Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

S&P Pharmaceuticals SPDR (NY: XPH )

48.30 USD -0.06 (-0.12%)
Official Closing Price Updated: 8:00 PM EDT, Sep 24, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about S&P Pharmaceuticals SPDR

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
ETF Flows Report for 09/24/2021
. orttr { font-family: Arial; font-size: 12pt; font-weight: bold; height: 24px; } . 
Tags ETFs
From ETF Channel
Is Now the Time to Ditch Pharma Stocks?
With drug pricing reform on the horizon, investors may want to analyze their allocation. 
Tags VRTX VTRS CRSP
From Motley Fool
2 Pharma Stocks You Can Buy and Hold for the Next Decade
Both stocks have grabbed plenty of headlines over the past year. 
Tags PFE XPH Market News
From Motley Fool
Analysts Predict 42% Gains Ahead For XPH
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Moderna stock extends rally after price target gets a 77% boost at Morgan Stanley
Shares of Moderna Inc. rallied toward a fifth straight gain Tuesday, after Morgan Stanley analyst Matthew Harrison added nearly $150 to his price target on an increased outlook for the biotechnology... 
Tags MRNA MRK GMAB
From MarketWatch
The Cost Of Saving The Economy: $1.7 Billion Per Hour Every Hour
the Fed has bought $4 trillion bonds in the past 18 months, twice the amount the US spent on War in Afghanistan past 20 years as it, and other global central banks, have spent $834 million every hour... 
Tags Market News
From TalkMarkets
3 Pharma Stocks to Buy in August
These stocks offer solid growth opportunities. 
Tags BAYR/Y Market News BIIB
From Motley Fool
The Math Shows XPH Can Go To $69
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
The 2 Best Pharma Stocks to Buy on Dips
Because the COVID-19 pandemic is under control in most major economies, the hype surrounding vaccine producers is gradually tapering off. 
Tags Stocks / Equities Market News Pharma/Biotech
From TalkMarkets
Analysts See 27% Gains Ahead For XPH
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
3 Top Pharma Stocks to Buy This Month
In 2020, pharmaceutical stocks came to the forefront as healthcare companies were searching for treatments for COVID-19. 
Tags Market News Pharma/Biotech Stocks / Equities
From TalkMarkets
How The Parts Add Up: XPH Targets $67
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
How The Pieces Add Up: XPH Headed For $67
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Pharma ETFs in Focus Post Q1 Earnings
The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. 
Tags ETFs Market News Pharma/Biotech
From TalkMarkets
Look Under The Hood: XPH Has 35% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
3 Pharmaceutical ETFs That Could Be Due For A Rebound
Here are three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. 
Tags Market News ETFs Pharma/Biotech
From TalkMarkets
3 Pharmaceutical ETFs That Could Be Due For A Rebound
These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration ... 
Tags Long Ideas PILL XPH
From Benzinga
Sum Up The Parts: XPH Could Be Worth $67
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Beyond COVID, Regeneron Is Betting Big on Oncology
Future growth will depend on its new checkpoint inhibitor wrangling market share away from Merck's Keytruda. 
Tags BMY REGN Market News
From Motley Fool
The Math Shows XPH Can Go To $68
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Implied XPH Analyst Target Price: $68
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Large Cap Biopharma Stalled With Move to Small Caps and Reflation Trade
Defensive large-cap biopharma stocks stalled as traders moved out on the risk curve seeking faster gains. 
Tags Stocks / Equities Pharma/Biotech Healthcare
From TalkMarkets
Pharma ETFs in Focus Post Q4 Earnings
The slew of Q4 results has led to mixed trading in pharma ETFs over the past 10 days. Here is a highlight of those in detail. 
Tags Healthcare ETFs
From TalkMarkets
Sum Up The Pieces: XPH Could Be Worth $67
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Analysts Anticipate XPH Will Reach $67
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Analysts See 28% Upside For The Holdings of XPH
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
How The Pieces Add Up: XPH Headed For $65
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
Big Pharma In Canada Offers C$1B In Last Attempt To Stop Drug Pricing Crackdown
The pharmaceutical industry has delivered aC$1 billion ($761 million) proposal to the Canadian government in an attempt to stave ... 
Tags Media Benzinga News
From Benzinga
Analysts Anticipate XPH To Hit $62
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
How The Parts Add Up: XPH Targets $60
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and... 
Tags ETFs
From ETF Channel
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.